Am J Transplant, Volume 19, Suppl 3 Archives - Page 79 of 214 - ATC Abstracts

2019 American Transplant Congress
Assessment of Physical Frailty is Positively Correlated with LAS Score in Lung Transplant Candidates
S. Jaladanki¹, L. Shih¹, O. Kwon², N. Ventigan², D. Nanayakkara², S. Weigt³, J. Singer⁴, A. Ardehali¹, R. Biniwale¹, D. Goldwater⁵, J. Schaenman²
¹Department of Cardiac Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Division of Pulmonary and Critical Care, UCSF School of Medicine, San Francisco, CA, ⁵Division of Geriatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: We proposed to evaluate physical frailty in lung transplant candidates to determine whether physical frailty correlated with LAS score and added to ability to…
2019 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies Improve Risk Stratification for Kidney Allograft Outcomes at the Time of Transplantation
C. Lefaucheur¹, D. Viglietti¹, Y. Bouatou¹, A. Philippe², D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Loupy¹, D. Dragun²
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²Medical Faculty of the Charité Berlin, Berlin, Germany
*Purpose: Current state-of-the-art pre-transplant risk stratification relies on the HLA system. Non-HLA agonistic angiotensin II type 1 receptor antibodies (AT1R-Ab) have been associated with allograft…
2019 American Transplant Congress
An International Comparison of Kidney Utilization in the United States and United Kingdom: What Can Be Learned?
D. Stewart¹, G. Vece¹, M. Ibrahim², C. Callaghan²
¹UNOS, Richmond, VA, ²NHS, London, United Kingdom
*Purpose: International discussions in 2017 about kidney “discard rates” between transplant (TX) professionals in the US and UK led to the realization that the two…
2019 American Transplant Congress
Cognitive Function & Risk Of Adverse Outcomes In Kidney Transplant Candidates
N. Chu¹, Z. Shi¹, H. Ying¹, C. Haugen¹, S. Norman², D. Segev¹, M. McAdams-DeMarco¹
¹JHU, Baltimore, MD, ²Michigan Medical Center, Ann Arbor, MI
*Purpose: With a high prevalence of cognitive impairment and underreported dementia--severe cognitive impairment that impairs activities of daily living--patients with ESRD may have reduced chance…
2019 American Transplant Congress
Assessment of Serum Tim3 and Gal9 Levels in Predicting the Risk of Infection after Kidney Transplantation
Y. Shi¹, y. li², Y. Li², L. Yan², J. Tang², X. Wu², Y. Bai², Y. An², B. Dai², C. Yang², L. Wang²
¹Department of Nephrology, West China Hospital, Chengdu, China, ²Department of Laboratory Medicine, West China Hospital, Chengdu, China
*Purpose: Infection remains a major cause of morbidity and mortality after kidney transplantation (KT). However, reliable biomarkers to predict the occurrence of post-transplant infection are…
2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
T. Yamamoto¹, H. Hara¹, J. Foote¹, E. C. Klein², H. J. Schuurman³, L. Wang¹, Q. Li¹, H. Zhou¹, J. Li¹, J. A. Tector¹, Z. Zhang², M. Ezzelarab², R. Lovingood¹, D. Ayares⁴, D. E. Eckhoff¹, D. K. Cooper¹, H. Iwase¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pittsburgh, Pittsburgh, PA, ³Schubiomed Consultancy, Utrecht, Netherlands, ⁴Revivicor, Blacksburg, VA
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…
2019 American Transplant Congress
External Validation of the DCD-N Score and a Linear Prediction Model to Identify Potential Candidates for Donation after Circulatory Death: A Nation-Wide Cohort Study
M. F. Nijhoff¹, R. A. Pol¹, M. Volbeda¹, A. M. Kotsopoulos², J. P. Sonneveld³, J. van Dongen⁴, W. F. Abdo⁵, V. Silderhuis⁶, C. Moers¹
¹Surgery – Organ Donation and Transplantation, University Medical Center Groningen, Groningen, Netherlands, ²Department of Intensive Care Unit (ICU), Elisabeth Twee Steden Hospital, Tilburg, Netherlands, ³Department of ICU, Isala, Zwolle, Netherlands, ⁴Department of ICU, Catharina hospital, Eindhoven, Netherlands, ⁵Department of ICU, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Department of ICU, Medisch Spectrum Twente, Enschede, Netherlands
*Purpose: Donation after circulatory death (DCD) is most often a controlled procedure after planned withdrawal of life-sustaining treatment (WLST) at an intensive care unit. In…
2019 American Transplant Congress
Renal Failure as a Complication of Vascularized Composite Allotransplantation
R. N. Barth¹, J. T. Shores², G. Brandacher², M. H. Levine³, A. Weissenbacher⁴, A. J. Nam¹, N. Shockcor¹, E. D. Rodriguez⁵, S. Schneeberger⁴, W. Lee², S. T. Bartlett¹, L. Levin³
¹University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Pennsylvania School of Medicine, Philadelphia, PA, ⁴Medical University Innsbruck, Innsbruck, Austria, ⁵New York University School of Medicine, New York, NY
*Purpose: Vascularized composite allotransplantation (VCA) has demonstrated impressive outcomes in areas of extremity (UETx), face (FTx), genitourinary, and abdominal wall transplantation with up to twenty…
2019 American Transplant Congress
Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection
J. Choi¹, E. Huang¹, O. Aubert², A. Vo¹, A. Peng¹, R. Najjar¹, S. Sethi¹, N. Ammerman¹, K. Lim¹, D. Puliyanda¹, A. Loupy², S. Jordan¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ²Paris Translational Center for Organ Transplantation, Paris, France
*Purpose: Limited options exist for the treatment of kidney allograft rejection and preservation of allograft function. We reported our experience with anti-IL-6R (tocilizumab, TCZ) as…
2019 American Transplant Congress
Reduction in Waitlist Time Using HCV Positive Liver Grafts in HCV Negative Recipients
E. M. Bugeaud, N. Bzowej, J. Hand, J. Scheuermann, H. Bohorquez, C. Brown, D. Bruce, I. Carmody, A. Cohen, S. Joshi, N. Latt, J. Seal, D. Sonnier, G. Therapondos, G. Tyson, N. Girgrah, G. Loss
Ochsner Health System, New Orleans, LA
*Purpose: With direct-acting antiviral (DAA) therapy, we feel that HCV+ organs are safe for all patients regardless of their HCV status and have adopted a…